FDA Approved: ZORYVE — Supplemental Application (Arcutis Biotherapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZORYVE (roflumilast) from Arcutis Biotherapeutics, resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ZORYVE (ROFLUMILAST)

Snippet

SUPPL AP for ZORYVE (ROFLUMILAST)